Business · 06/05/2011

FDA Guidance on Submitting Summary Bioequivalence Data for Generic Drug Applications

The FDA has released a guidance document to help pharmaceutical companies comply with regulations for submitting bioequivalence data for generic drug applications. The guidance aims to assist applicants in meeting the requirements for submitting data from bioequivalence studies, which are studies that demonstrate a generic product meets the current bioequivalence criteria.